The Jreissati Pancreatic Centre at Epworth strives to improve early detection of pancreatic cancer through high-risk surveillance and research into precursor lesions and associated pancreatic conditions. As noted in the media recently, a recent test for early pancreatic cancer detection has been launched in Australia - the Avantect Pancreatic Cancer Test. Research is underway into the effectiveness and accuracy of this test, and its position in the diagnostic pathway.

In partnership with BCal Diagnostics, the JPCE facilitates access to the Avantect Pancreatic Cancer Test, for individuals who wish to use it. If you or your loved ones wishes to access the test privately (i.e., out-of-pocket), please see the documents below. They include key patient information about the testing service as well as ClearNote referral forms for pathology providers Melbourne Pathology and Dorevitch, that you will need to provide to your primary physician.

Private access to the test incurs an out-of-pocket cost of $1,495 AUD. Please note, Medicare and the JPCE do not finance the test at this stage.

Whilst the JPCE is excited about this development, it is at an early stage of testing and is not current standard of care. It is not a replacement for existing surveillance measures such as the APRISE program. We strongly recommend that it only be used alongside standard screening and clinical advice.

As always, please seek medical advice from your primary physician before making any decisions.